Advertisements



Goldman says Bristol-Myers reaction to NSCLC data, Merck news "way overdone"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol reaction to NSCLC data, Merck news "way overdone," says Goldman Sachs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Friday’s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Options trading was buzzi.....»»

Category: topSource: investorplaceFeb 16th, 2019

Friday’s Vital Data: Apple, American Airlines and Bristol-Myers

InvestorPlace - Stock Market News, Stock Advice & Trading Tip.....»»

Category: topSource: investorplaceJan 4th, 2019

Bristol-Myers announces CNDA approval of Opdivo for NSCLC treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Nektar, Bristol-Myers announce preliminary data from PIVOT Phase 1/2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Bristol-Myers reports patient-reported outcomes data from CheckMate-214 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

Bristol-Myers downgraded on lung cancer data disappointment at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot.....»»

Category: topSource: seekingalphaApr 17th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Nektar shares drop 16% to $84.50 after Bristol-Myers cancer data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -0.....»»

Category: worldSource: nytApr 16th, 2018

Merck rises, Bristol-Myers slides following cancer meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Smith says Bristol-Myers bid values Celgene for 10 upcoming blockbusters

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 22nd, 2019

Starboard"s Smith says Bristol-Myers does not need to do any deal

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 22nd, 2019

Biotech Analysis Central Pharma News: AbbVie"s Trouble, Merck KGaA"s Bad Streak, Puma"s Positive Data

Biotech Analysis Central Pharma News: AbbVie"s Trouble, Merck KGaA"s Bad Streak, Puma"s Positive Data.....»»

Category: topSource: seekingalphaMar 20th, 2019

Bristol-Myers price target raised to $62 from $59 at BMO Capital

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 20th, 2019

Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Zacks.....»»

Category: topSource: redinewsMar 19th, 2019

Starboard files presentation opposing Bristol-Myers" proposed acquistion of Celgene

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2019

Bristol-Myers announces filing of presentation on Celgene deal benefits

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2019

Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (V.....»»

Category: dealsSource: nytMar 18th, 2019